For the quarter ending 2026-03-31, CBIO had -$24,029K decrease in cash & cash equivalents over the period. -$9,084K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| License revenue | - | 10,844 | - | - |
| Research and development expense-CR001 | - | 44,958 | - | - |
| Research and development expense-CR002 | - | 20,321 | - | - |
| Research and development expense-Discovery External Research And Development Costs | - | 1,952 | - | - |
| Personnel costs | - | 31,022 | - | - |
| Milestone and license fees | - | 84,710 | - | - |
| Professional and other fees | - | 17,461 | - | - |
| Other expense (income) | - | -690 | - | - |
| Provision for income taxes | - | 2,000 | - | - |
| Net loss | -23,283 | -92,397 | -61,545 | - |
| Share-based compensation expense | 4,113 | 4,745 | 1,986 | 6,569 |
| Research and development license expense | - | 80,000 | - | - |
| Depreciation expense | 64 | 54 | 28 | 2 |
| Non-cash interest expense | 0 | 0 | 0 | 2,185 |
| Non-cash research and development expense related to paragon option agreement | - | 0 | 0 | - |
| Non-cash lease expense | 97 | 95 | 94 | 23 |
| Accounts payable-Nonrelated Party | -2,312 | 1,024 | 1,488 | -431 |
| Accrued expenses and other current liabilities-Nonrelated Party | - | - | 2,005 | 4,417 |
| Accrued expenses and other current liabilities | -3,456 | 5,363 | - | - |
| Related party accounts payable and other current liabilities-Related Party | -140 | -6,133 | 1,090 | -2,038 |
| Deferred revenue | -1,039 | 4,156 | - | - |
| Deposit liability | - | 5,000 | - | - |
| Operating lease liability | -101 | -97 | 46 | 14 |
| Accounts receivable | -18,000 | 18,000 | - | - |
| Prepaid expenses and other current assets | 937 | 4,165 | -284 | 1,134 |
| Other assets | -57 | -37 | -47 | -78 |
| Net cash used in operating activities | -8,937 | -26,740 | -17,539 | -27,253 |
| Purchase of research and development license | 8,000 | 72,000 | - | - |
| Purchases of property and equipment | 147 | 193 | 586 | 140 |
| Net cash used in investing activities | -8,147 | -72,193 | -586 | -140 |
| Proceeds from the pre-closing financing, net | - | -20 | -1,254 | 144,281 |
| Proceeds from the private placement financing, net | - | 178,880 | - | - |
| Cash acquired in connection with the reverse recapitalization | - | 0 | 0 | 1,269 |
| Proceeds from early exercise of options | 0 | 0 | 0 | 5 |
| Proceeds from issuance of common stock | - | 0 | - | - |
| Proceeds from issuance of series seed convertible preferred stock | - | 0 | - | - |
| Proceeds from the issuance of notes payable, net of issuance costs | - | 0 | - | - |
| Payment of debt issuance costs | 0 | - | - | - |
| Payment of deferred offering costs | 6,945 | 0 | - | - |
| Repurchase of equity awards | - | 0 | 0 | -177 |
| Net cash used in financing activities | -6,945 | 178,860 | -1,254 | 145,378 |
| Net decrease in cash, cash equivalents, and restricted cash | -24,029 | 79,927 | -19,379 | 117,985 |
| Cash, cash equivalents, and restricted cash at beginning of period | 213,299 | 133,372 | 34,766 | - |
| Cash, cash equivalents, and restricted cash at end of period | 189,270 | 213,299 | 133,372 | - |
CRESCENT BIOPHARMA, INC. (CBIO)
CRESCENT BIOPHARMA, INC. (CBIO)